Henry Chambers, III, MD
Professor
Medicine
School of Medicine

He is editor for the Sanford Guide to Antimicrobial Therapy and he has over 200 original publications and textbook chapters in the areas of drug resistance, endocarditis, bacterial infections, and staphylococcal diseases. Dr. Chambers received his BA from Centre College in Kentucky and is a graduate of the Vanderbilt University School of Medicine. He trained in Internal Medicine and Infectious Diseases at the University of California San Francisco. Dr. Chambers has been a member of the medical faculty of the UCSF since 1983 where he currently is Professor of Medicine, Medical Director of Clinical Research Services for CTSI. He is an editor for Antimicrobial Agents and Chemotherapy, a reviewer for numerous medical publications, a peer reviewer for NIH study sections.

• Spatial clusters of dominant lineages of uropathogenic Escherichia coli in a community dwelling patient population.
  Research square 2025 Belmont C, Inamdar P, Shariff-Marco S, Gul A, Huang AJ, Chambers HF, Raphael E
• Intention-to-diagnose and distinct research foci in diagnostic accuracy studies.
  The Lancet. Infectious diseases 2025 Evans SR, Pennello G, Zhang S, Li Y, Wang Y, Cao Q, Komarow L, Hamasaki T, Petrides V, Meier K, Galicia NP, Fowler VG, Boucher HW, Doernberg SB, Banerjee R, Rigatto MH, Kreiswirth BN, Bonomo RA, …
• NaHCO3 modulates the bla operon and β-lactam susceptibility in borderline oxacillin-resistant Staphylococcus aureus (BORSA).
  The Journal of antimicrobial chemotherapy 2025 Ersoy SC, Madrigal SL, Proctor RA, Chambers HF, Xiong YQ, Bayer AS
• International Expert Opinion on Standard of Care for Patients With Schinzel-Giedion Syndrome: A Modified Delphi Study.
  American journal of medical genetics. Part A 2025 Duis J, Agresta L, Bennett WE, Chambers H, Clarke A, Fairhurst C, Hoover-Fong J, Murphy F, Noritz G, Schwantes S, Shreve M, Thusang K, Weidemann D, Beale R, Mehta A, Wilhelmsen A, Summerfield N
• The Positioning of Ceftobiprole in the Treatment of Staphylococcus aureus Bacteremia.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2024 Minter DJ, Appa A, Chambers HF, Doernberg SB
• Phenotypic and genotypic correlates of the sodium bicarbonate-responsive phenotype among methicillin-resistant Staphylococcus aureus isolates from skin and soft-tissue infections.
  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2024 Ersoy SC, Madrigal SL, Chen L, Mediavilla J, Kreiswirth B, Flores EA, Miller LG, Xiong YQ, Harrison EM, Blane B, Peacock SJ, Patel R, Chambers HF, Bayer AS, Proctor RA
• Intertwining clonality and resistance: Staphylococcus aureus in the antibiotic era.
  The Journal of clinical investigation 2024 Chambers HF, Fowler VG
• Characterization of Gram-negative Bloodstream Infections in Hospitalized Australian Children and Their Clinical Outcomes.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2024 Wen SCH, Harris PNA, Forde B, Permana B, Chatfield MD, Lau CL, Spurling G, Bauer MJ, Balch R, Chambers H, Schlapbach LJ, Clark JE, Dougherty S, Blyth CC, Britton PN, Clifford V, Haeusler GM, McMullan …
• A molecular analysis of meropenem-vaborbactam non-susceptible KPC-producing Klebsiella pneumoniae.
  Antimicrobial agents and chemotherapy 2024 Yasmin M, Marshall SH, Chen L, Rhoads DD, Jacobs MR, Rojas LJ, Perez F, Hujer AM, Hujer KM, van Duin D, Fowler V, Chambers HF, Kreiswirth BN, Bonomo RA, Antibacterial Resistance Leadership Group
• Exploration of a Potential DOOR Endpoint for Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia Using Six Registrational Trials for Antibacterial Drugs.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2024 Kinamon T, Waack U, Needles M, Rubin D, Collyar D, Doernberg SB, Evans SR, Hamasaki T, Holland TL, Howard-Anderson J, Chambers H, Fowler VG, Nambiar S, Kim P, Boucher HW, Gopinath R
• Participant Diversity in United States Randomized Controlled Trials of Antibacterials for Staphylococcus aureus Infections, 2000-2021.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2024 Kwon J, Pelletiers W, Galloway Peña J, van Duin D, Ledbetter L, Baum K, Ruffin F, Knisely JM, Bizzell E, Fowler VG, Chambers HF, Pettigrew MM
• Duke Infective Endocarditis Criteria 3.0 for the Clinician: Defining What Is Possible.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2024 Chambers HF, Zhang S, Evans S
• Altered PBP4 and GdpP functions synergistically mediate MRSA-like high-level, broad-spectrum β-lactam resistance in Staphylococcus aureus.
  mBio 2024 Lai L-Y, Satishkumar N, Cardozo S, Hemmadi V, Marques LB, Huang L, Filipe SR, Pinho MG, Chambers HF, Chatterjee SS
• Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter baumannii Among Patients From Different Global Regions.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2024 Wang M, Ge L, Chen L, Komarow L, Hanson B, Reyes J, Cober E, Alenazi T, Zong Z, Xie Q, Liu Z, Li L, Yu Y, Gao H, Kanj SS, Figueroa J, Herc E, Cordova E, Weston G, Ananth Tambyah P, Garcia-Diaz J, Kaye…
• Moving Beyond Mortality: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2024 Howard-Anderson J, Hamasaki T, Dai W, Collyar D, Rubin D, Nambiar S, Kinamon T, Leister-Tebbe H, Hill C, Geres H, Holland TL, Doernberg SB, Chambers HF, Fowler VG, Evans SR, Boucher HW, Antibacterial …
• Sensitizing methicillin-resistant Staphylococcus aureus (MRSA) to cefuroxime: the synergic effect of bicarbonate and the wall teichoic acid inhibitor ticlopidine.
  Antimicrobial agents and chemotherapy 2024 Ersoy SC, Proctor RA, Rose WE, Abdelhady W, Fan S-H, Madrigal SL, Elsayed AM, Chambers HF, Sobral RG, Bayer AS
• In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals.
  Antimicrobial agents and chemotherapy 2024 Iovleva A, McElheny CL, Fowler EL, Cober E, Herc ES, Arias CA, Hill C, Baum K, Fowler VG, Chambers HF, Greenwood-Quaintance KE, Patel R, van Duin D, Bonomo RA, Doi Y
• Contemporary Management of Staphylococcus aureus Bacteremia-Controversies in Clinical Practice.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2023 Minter DJ, Appa A, Chambers HF, Doernberg SB
• Executive Summary: State-of-The-Art Review: Contemporary Management of Staphylococcus aureus Bacteremia: Controversies in Clinical Practice.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2023 Minter DJ, Appa A, Chambers HF, Doernberg SB
• Altered PBP4 and GdpP functions synergistically mediate MRSA-like high-level, broad-spectrum β-lactam resistance in Staphylococcus aureus.
  bioRxiv : the preprint server for biology 2023 Lai LY, Satishkumar N, Cardozo S, Hemmadi V, Marques LB, Huang L, Filipe SR, Pinho MG, Chambers HF, Chatterjee SS
• Spatial clusters of extended-spectrum beta-lactamase-producing Escherichia coli causing community-onset bacteriuria due to repeat infections: cluster analysis from a large urban medical center, San Francisco, 2014-2020.
  Antimicrobial resistance and infection control 2023 Raphael E, Inamdar PP, Belmont C, Shariff-Marco S, Huang AJ, Chambers HF
• The Antibacterial Resistance Leadership Group: Scientific Advancements and Future Directions.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2023 Chambers HF, Cross HR, Souli M, Evans SR, Patel R, Fowler VG, Antibacterial Resistance Leadership Group
• The Future Ain't What It Used to Be…Out With the Old…In With the Better: Antibacterial Resistance Leadership Group Innovations.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2023 Evans SR, Patel R, Hamasaki T, Howard-Anderson J, Kinamon T, King HA, Collyar D, Cross HR, Chambers HF, Fowler VG, Boucher HW, Antibacterial Resistance Leadership Group
• Under the Hood: The Scientific Leadership, Clinical Operations, Statistical and Data Management, and Laboratory Centers of the Antibacterial Resistance Leadership Group.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2023 Cross HR, Greenwood-Quaintance KE, Souli M, Komarow L, Geres HS, Hamasaki T, Chambers HF, Fowler VG, Evans SR, Patel R, Antibacterial Resistance Leadership Group
• Daily fosfomycin versus levofloxacin for complicated urinary tract infections.
  mBio 2023 Rouphael N, Winokur P, Keefer MC, Traenkner J, Drobeniuc A, Doi Y, Munsiff S, Fowler VG, Evans S, Oler RE, Tuyishimire B, Lee M, Ghazaryan V, Chambers HF, DMID 15-0045 study group
• Exploration of a Potential Desirability of Outcome Ranking Endpoint for Complicated Intra-Abdominal Infections Using 9 Registrational Trials for Antibacterial Drugs.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2023 Kinamon T, Gopinath R, Waack U, Needles M, Rubin D, Collyar D, Doernberg SB, Evans S, Hamasaki T, Holland TL, Howard-Anderson J, Chambers H, Fowler VG, Nambiar S, Kim P, Boucher HW
• International Epidemiology of Carbapenemase-Producing Escherichia coli.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2023 Boutzoukas AE, Komarow L, Chen L, Hanson B, Kanj SS, Liu Z, Salcedo Mendoza S, Ordoñez K, Wang M, Paterson DL, Evans S, Ge L, Giri A, Hill C, Baum K, Bonomo RA, Kreiswirth B, Patel R, Arias CA, …
• Spatial clusters of extended-spectrum beta-lactamase-producing Escherichia coli causing community-onset bacteriuria due to repeat infections: cluster analysis from a large urban medical center, San Francisco, 2014-2020.
  Research square 2023 Raphael E, Inamdar PP, Belmont C, Shariff-Marco S, Huang A, Chambers H
• Role of the NaHCO3 Transporter MpsABC in the NaHCO3-β-Lactam-Responsive Phenotype in Methicillin-Resistant Staphylococcus aureus.
  Microbiology spectrum 2023 Fan SH, Proctor RA, Ersoy SC, Manna AC, Cheung AL, Götz F, Chambers HF, Bayer AS
• Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study.
  The Lancet. Microbe 2023 Reyes J, Komarow L, Chen L, Ge L, Hanson BM, Cober E, Herc E, Alenazi T, Kaye KS, Garcia-Diaz J, Li L, Kanj SS, Liu Z, Oñate JM, Salata RA, Marimuthu K, Gao H, Zong Z, Valderrama-Beltrán SL, Yu Y, …
• Improving Traditional Registrational Trial End Points: Development and Application of a Desirability of Outcome Ranking End Point for Complicated Urinary Tract Infection Clinical Trials.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2023 Howard-Anderson J, Hamasaki T, Dai W, Collyar D, Rubin D, Nambiar S, Kinamon T, Hill C, Gelone SP, Mariano D, Baba T, Holland TL, Doernberg SB, Chambers HF, Fowler VG, Evans SR, Boucher HW
• Structural basis of broad-spectrum β-lactam resistance in Staphylococcus aureus.
  Nature 2023 Alexander JAN, Worrall LJ, Hu J, Vuckovic M, Satishkumar N, Poon R, Sobhanifar S, Rosell FI, Jenkins J, Chiang D, Mosimann WA, Chambers HF, Paetzel M, Chatterjee SS, Strynadka NCJ
• Safety and microbiological activity of phage therapy in persons with cystic fibrosis colonized with Pseudomonas aeruginosa: study protocol for a phase 1b/2, multicenter, randomized, double-blind, placebo-controlled trial.
  Trials 2022 Tamma PD, Souli M, Billard M, Campbell J, Conrad D, Ellison DW, Evans B, Evans SR, Greenwood-Quaintance KE, Filippov AA, Geres HS, Hamasaki T, Komarow L, Nikolich MP, Lodise TP, Nayak SU, Norice-Tra C…
• Pharmacokinetics of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase 1, Open-Label Study of Healthy Adults.
  Antimicrobial agents and chemotherapy 2022 Lodise TP, O'Donnell JN, Balevic S, Liu X, Gu K, George J, Raja S, Guptill JT, Zaharoff S, Schwager N, Fowler VG, Wall A, Wiegand K, Chambers HF, Antibacterial Resistance Leadership Group
• Safety of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase I, Open-Label Study in Healthy Adult Volunteers.
  Antimicrobial agents and chemotherapy 2022 Lodise TP, O'Donnell JN, Raja S, Guptill JT, Zaharoff S, Schwager N, Fowler VG, Beresnev T, Wall A, Wiegand K, Serti Chrisos E, Balevic S, Chambers HF, Antibacterial Resistance Leadership Group
• Influence of Sodium Bicarbonate on Wall Teichoic Acid Synthesis and β-Lactam Sensitization in NaHCO3-Responsive and Nonresponsive Methicillin-Resistant Staphylococcus aureus.
  Microbiology spectrum 2022 Ersoy SC, Gonçalves B, Cavaco G, Manna AC, Sobral RG, Nast CC, Proctor RA, Chambers HF, Cheung A, Bayer AS
• Clinical Impact of Ceftriaxone Resistance in Escherichia coli Bloodstream Infections: A Multicenter Prospective Cohort Study.
  Open forum infectious diseases 2022 Tamma PD, Komarow L, Ge L, Garcia-Diaz J, Herc ES, Doi Y, Arias CA, Albin O, Saade E, Miller LG, Jacob JT, Satlin MJ, Krsak M, Huskins WC, Dhar S, Shelburne SA, Hill C, Baum KR, Bhojani M, Greenwood-…
• Confronting antimicrobial resistance together.
  American journal of physiology. Lung cellular and molecular physiology 2022 Chambers HF, Fowler VG, Antibacterial Resistance Leadership Group
• Gastrointestinal Microbiome Disruption and Antibiotic-Associated Diarrhea in Children Receiving Antibiotic Therapy for Community-Acquired Pneumonia.
  The Journal of infectious diseases 2022 Kwon J, Kong Y, Wade M, Williams DJ, Creech CB, Evans S, Walter EB, Martin JM, Gerber JS, Newland JG, Hofto ME, Staat MA, Chambers HF, Fowler VG, Huskins WC, Pettigrew MM
• The NaHCO3-Responsive Phenotype in Methicillin-Resistant Staphylococcus aureus (MRSA) Is Influenced by mecA Genotype.
  Antimicrobial agents and chemotherapy 2022 Ersoy SC, Manna AC, Proctor RA, Chambers HF, Harrison EM, Bayer AS, Cheung A
• A Desirability of Outcome Ranking Analysis of a Randomized Clinical Trial Comparing Seven Versus Fourteen Days of Antibiotics for Uncomplicated Gram-Negative Bloodstream Infection.
  Open forum infectious diseases 2022 Howard-Anderson J, Dai W, Yahav D, Hamasaki T, Turjeman A, Koppel F, Franceschini E, Hill C, Sund Z, Chambers HF, Fowler VG, Boucher HW, Evans SR, Paul M, Holland TL, Doernberg SB
• Anterior distal femoral hemiepiphysiodesis in children with cerebral palsy: Establishing surgical indications and techniques using the modified Delphi method and literature review.
  Journal of children's orthopaedics 2022 Shore BJ, McCarthy J, Shrader MW, Graham HK, Veerkamp M, Rutz E, Chambers H, Davids JR, Narayanan U, Novacheck TF, Pierz K, Dreher T, Rhodes J, Shilt J, Theologis T, Van Campenhout A, Kay RM
• Finding consensus for hamstring surgery in ambulatory children with cerebral palsy using the Delphi method.
  Journal of children's orthopaedics 2022 Kay RM, McCarthy J, Narayanan U, Rhodes J, Rutz E, Shilt J, Shore BJ, Veerkamp M, Shrader MW, Theologis T, Van Campenhout A, Pierz K, Chambers H, Davids JR, Dreher T, Novacheck TF, Graham K
• Accessory Genomes Drive Independent Spread of Carbapenem-Resistant Klebsiella pneumoniae Clonal Groups 258 and 307 in Houston, TX.
  mBio 2022 Shropshire WC, Dinh AQ, Earley M, Komarow L, Panesso D, Rydell K, Gómez-Villegas SI, Miao H, Hill C, Chen L, Patel R, Fries BC, Abbo L, Cober E, Revolinski S, Luterbach CL, Chambers H, Fowler VG, …
• Impacts of NaHCO3 on β-Lactam Binding to PBP2a Protein Variants Associated with the NaHCO3-Responsive versus NaHCO3-Non-Responsive Phenotypes.
  Antibiotics (Basel, Switzerland) 2022 Ersoy SC, Chan LC, Yeaman MR, Chambers HF, Proctor RA, Ludwig KC, Schneider T, Manna AC, Cheung A, Bayer AS
• Short- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in Children: The SCOUT-CAP Randomized Clinical Trial.
  JAMA pediatrics 2022 Williams DJ, Creech CB, Walter EB, Martin JM, Gerber JS, Newland JG, Howard L, Hofto ME, Staat MA, Oler RE, Tuyishimire B, Conrad TM, Lee MS, Ghazaryan V, Pettigrew MM, Fowler VG, Chambers HF, Zaoutis…
• Comparative 1-Year Outcomes of Invasive Staphylococcus aureus Infections Among Persons With and Without Drug Use: An Observational Cohort Study.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2022 Appa A, Adamo M, Le S, Davis J, Winston L, Doernberg SB, Chambers H, Martin M, Hills NK, Coffin PO, Jain V
• Associations Between Vancomycin Exposure and Acute Kidney Injury Within the Recommended Area Under the Curve Therapeutic Exposure Range Among Patients With Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.
  Open forum infectious diseases 2022 Lodise TP, Scheetz M, Carreno JJ, Chambers H, Fowler V, Holland TL
• Loss of GdpP Function in Staphylococcus aureus Leads to β-Lactam Tolerance and Enhanced Evolution of β-Lactam Resistance.
  Antimicrobial agents and chemotherapy 2021 Poon R, Basuino L, Satishkumar N, Chatterjee A, Mukkayyan N, Buggeln E, Huang L, Nair V, Argudín MA, Datta SK, Chambers HF, Chatterjee SS
• Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study.
  The Lancet. Infectious diseases 2021 Wang M, Earley M, Chen L, Hanson BM, Yu Y, Liu Z, Salcedo S, Cober E, Li L, Kanj SS, Gao H, Munita JM, Ordoñez K, Weston G, Satlin MJ, Valderrama-Beltrán SL, Marimuthu K, Stryjewski ME, Komarow L, …
• Impact of Bicarbonate-β-Lactam Exposures on Methicillin-Resistant Staphylococcus aureus (MRSA) Gene Expression in Bicarbonate-β-Lactam-Responsive vs. Non-Responsive Strains.
  Genes 2021 Ersoy SC, Hanson BM, Proctor RA, Arias CA, Tran TT, Chambers HF, Bayer AS
• Oral versus Intravenous Antibiotics for Endocarditis.
  The New England journal of medicine 2021 Chowdhury J, Patel R, Chambers H
• A Combined Phenotypic-Genotypic Predictive Algorithm for In Vitro Detection of Bicarbonate: β-Lactam Sensitization among Methicillin-Resistant Staphylococcus aureus (MRSA).
  Antibiotics (Basel, Switzerland) 2021 Ersoy SC, Rose WE, Patel R, Proctor RA, Chambers HF, Harrison EM, Pak Y, Bayer AS
• Patient-Directed Discharges Among Persons Who Use Drugs Hospitalized with Invasive Staphylococcus aureus Infections: Opportunities for Improvement.
  The American journal of medicine 2021 Appa A, Adamo M, Le S, Davis J, Winston L, Doernberg SB, Chambers H, Martin M, Hills NK, Coffin P, Jain V
• Antibacterial Resistance Leadership Group 2.0: Back to Business.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2021 Chambers HF, Evans SR, Patel R, Cross HR, Harris AD, Doi Y, Boucher HW, van Duin D, Tsalik EL, Holland TL, Pettigrew MM, Tamma PD, Hodges KR, Souli M, Fowler VG
• Trends in prevalence of extended-spectrum beta-lactamase-producing Escherichia coli isolated from patients with community- and healthcare-associated bacteriuria: results from 2014 to 2020 in an urban safety-net healthcare system.
  Antimicrobial resistance and infection control 2021 Raphael E, Glymour MM, Chambers HF
• Distal rectus femoris surgery in children with cerebral palsy: results of a Delphi consensus project.
  Journal of children's orthopaedics 2021 Kay RM, Pierz K, McCarthy J, Graham HK, Chambers H, Davids JR, Narayanan U, Novacheck TF, Rhodes J, Rutz E, Shilt J, Shore BJ, Veerkamp M, Shrader MW, Theologis T, Van Campenhout A, Dreher T
• Prosthetic Valve Endocarditis Diagnosis and Management- New Paradigm Shift Narratives.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2021 Bayer AS, Chambers HF
• Impact of Bicarbonate on PBP2a Production, Maturation, and Functionality in Methicillin-Resistant Staphylococcus aureus (MRSA).
  Antimicrobial agents and chemotherapy 2021 Ersoy SC, Chambers HF, Proctor RA, Rosato AE, Mishra NN, Xiong YQ, Bayer AS
• Skin and Soft Tissue Infections.
  Infectious disease clinics of North America 2021 Chambers HF
• Importance of non-pharmaceutical interventions in lowering the viral inoculum to reduce susceptibility to infection by SARS-CoV-2 and potentially disease severity.
  The Lancet. Infectious diseases 2021 Spinelli MA, Glidden DV, Gennatas ED, Bielecki M, Beyrer C, Rutherford G, Chambers H, Goosby E, Gandhi M
• Skin and Soft Tissue Infections in Persons Who Inject Drugs.
  Infectious disease clinics of North America 2020 Chambers HF
• Simultaneous Evaluation of Diagnostic Assays for Pharyngeal and Rectal Neisseria gonorrhoeae and Chlamydia trachomatis Using a Master Protocol.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2020 Doernberg SB, Komarow L, Tran TTT, Sund Z, Pandori MW, Jensen D, Tsalik EL, Deal CD, Chambers HF, Fowler VG, Evans SR, Patel R, Klausner JD
• Indications for gastrocsoleus lengthening in ambulatory children with cerebral palsy: a Delphi consensus study.
  Journal of children's orthopaedics 2020 Rutz E, McCarthy J, Shore BJ, Shrader MW, Veerkamp M, Chambers H, Davids JR, Kay RM, Narayanan U, Novacheck TF, Pierz K, Rhodes J, Shilt J, Theologis T, Van Campenhout A, Dreher T, Graham K
• Rifabutin to the Rescue?
  The Journal of infectious diseases 2020 Chambers HF
• Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model.
  The Journal of antimicrobial chemotherapy 2020 Lodise TP, Smith NM, O'Donnell N, Eakin AE, Holden PN, Boissonneault KR, Zhou J, Tao X, Bulitta JB, Fowler VG, Chambers HF, Bonomo RA, Tsuji BT
• Native-Valve Infective Endocarditis.
  The New England journal of medicine 2020 Chambers HF, Bayer AS
• Differential Trends in Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Infections in Four Health Care Facilities in a Single Metropolitan Area: A Retrospective Analysis.
  Microbial drug resistance (Larchmont, N.Y.) 2020 Raphael E, Chambers HF
• Structural analysis of avibactam-mediated activation of the bla and mec divergons in methicillin-resistant Staphylococcus aureus.
  The Journal of biological chemistry 2020 Alexander JAN, Radaeva M, King DT, Chambers HF, Cherkasov A, Chatterjee SS, Strynadka NCJ
• Evaluation of a Paradigm Shift From Intravenous Antibiotics to Oral Step-Down Therapy for the Treatment of Infective Endocarditis: A Narrative Review.
  JAMA internal medicine 2020 Spellberg B, Chambers HF, Musher DM, Walsh TL, Bayer AS
• Scope and Predictive Genetic/Phenotypic Signatures of Bicarbonate (NaHCO3) Responsiveness and β-Lactam Sensitization in Methicillin-Resistant Staphylococcus aureus.
  Antimicrobial agents and chemotherapy 2020 Ersoy SC, Otmishi M, Milan VT, Li L, Pak Y, Mediavilla J, Chen L, Kreiswirth B, Chambers HF, Proctor RA, Xiong YQ, Fowler VG, Bayer AS
• The Emperor's New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE).
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2020 Lodise TP, Rosenkranz SL, Finnemeyer M, Evans S, Sims M, Zervos MJ, Creech CB, Patel PC, Keefer M, Riska P, Silveira FP, Scheetz M, Wunderink RG, Rodriguez M, Schrank J, Bleasdale SC, Schultz S, …
• Analytical Evaluation of the Abbott RealTime CT/NG Assay for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in Rectal and Pharyngeal Swabs.
  The Journal of molecular diagnostics : JMD 2020 Adamson PC, Pandori MW, Doernberg SB, Komarow L, Sund Z, Tran TTT, Jensen D, Tsalik EL, Deal CD, Chambers HF, Fowler VG, Evans SR, Patel R, Klausner JD, Antibacterial Resistance Leadership Group
• Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study.
  The Lancet. Infectious diseases 2020 van Duin D, Arias CA, Komarow L, Chen L, Hanson BM, Weston G, Cober E, Garner OB, Jacob JT, Satlin MJ, Fries BC, Garcia-Diaz J, Doi Y, Dhar S, Kaye KS, Earley M, Hujer AM, Hujer KM, Domitrovic TN, …
• Ability of Bicarbonate Supplementation To Sensitize Selected Methicillin-Resistant Staphylococcus aureus Strains to β-Lactam Antibiotics in an Ex Vivo Simulated Endocardial Vegetation Model.
  Antimicrobial agents and chemotherapy 2020 Rose WE, Bienvenida AM, Xiong YQ, Chambers HF, Bayer AS, Ersoy SC
• Antimicrobial Drug Development Efficiency and Surrogate Markers of Clinical Benefit.
  JAMA internal medicine 2020 Volberding P, Chambers HF
• Is Daptomycin plus Ceftaroline Associated with Better Clinical Outcomes than Standard of Care Monotherapy for Staphylococcus aureus Bacteremia?
  Antimicrobial agents and chemotherapy 2019 Kalil AC, Holubar M, Deresinski S, Chambers HF
• Clinical Practice Variation Among Adult Infectious Disease Physicians in the Management of Staphylococcus aureus Bacteremia.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2019 Liu C, Strnad L, Beekmann SE, Polgreen PM, Chambers HF
• Prevalence, Patterns, and Cost of Care for Children with Cerebral Palsy Enrolled in Medicaid Managed Care.
  Journal of managed care & specialty pharmacy 2019 Pulgar S, Bains S, Gooch J, Chambers H, Noritz GH, Wright E, Sawhney TG, Pyenson B, Ferro C
• Bicarbonate Resensitization of Methicillin-Resistant Staphylococcus aureus to β-Lactam Antibiotics.
  Antimicrobial agents and chemotherapy 2019 Ersoy SC, Abdelhady W, Li L, Chambers HF, Xiong YQ, Bayer AS
• Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2019 Evans SR, Tran TTT, Hujer AM, Hill CB, Hujer KM, Mediavilla JR, Manca C, Domitrovic TN, Perez F, Farmer M, Pitzer KM, Wilson BM, Kreiswirth BN, Patel R, Jacobs MR, Chen L, Fowler VG, Chambers HF, …
• Sequential, Multiple-Assignment, Randomized Trials for COMparing Personalized Antibiotic StrategieS (SMART-COMPASS).
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2019 Evans SR, Follmann D, Liu Y, Holland T, Doernberg SB, Rouphael N, Hamasaki T, Jiang Y, Lok JJ, Tran TTT, Harris AD, Fowler VG, Boucher H, Kreiswirth BN, Bonomo RA, Van Duin D, Paterson DL, Chambers H
• Good Studies Evaluate the Disease While Great Studies Evaluate the Patient: Development and Application of a Desirability of Outcome Ranking Endpoint for Staphylococcus aureus Bloodstream Infection.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2019 Doernberg SB, Tran TTT, Tong SYC, Paul M, Yahav D, Davis JS, Leibovici L, Boucher HW, Corey GR, Cosgrove SE, Chambers HF, Fowler VG, Evans SR, Holland TL, Antibacterial Resistance Leadership Group
• A Prognostic Model of Persistent Bacteremia and Mortality in Complicated Staphylococcus aureus Bloodstream Infection.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2019 Guimaraes AO, Cao Y, Hong K, Mayba O, Peck MC, Gutierrez J, Ruffin F, Carrasco-Triguero M, Dinoso JB, Clemenzi-Allen A, Koss CA, Maskarinec SA, Chambers HF, Fowler VG, Baruch A, Rosenberger CM
• Sustained Circulating Bacterial Deoxyribonucleic Acid Is Associated With Complicated Staphylococcus aureus Bacteremia.
  Open forum infectious diseases 2019 Gutierrez J, Guimaraes AO, Lewin-Koh N, Berhanu A, Xu M, Cao Y, Kim J, Yan D, Chang JK, Dinoso JB, Koss CA, Clemenzi-Allen A, Chambers HF, Peck MC, Baruch A, Rosenberger CM
• Considerations for Clinical Trials of Staphylococcus aureus Bloodstream Infection in Adults.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2019 Holland TL, Chambers HF, Boucher HW, Corey GR, Coleman R, Castaneda-Ruiz B, Fowler VG
• Omadacycline - The Newest Tetracycline.
  The New England journal of medicine 2019 Chambers HF
• Structural and kinetic analyses of penicillin-binding protein 4 (PBP4)-mediated antibiotic resistance in Staphylococcus aureus.
  The Journal of biological chemistry 2018 Alexander JAN, Chatterjee SS, Hamilton SM, Eltis LD, Chambers HF, Strynadka NCJ
• Essential Resources and Strategies for Antibiotic Stewardship Programs in the Acute Care Setting.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2018 Doernberg SB, Abbo LM, Burdette SD, Fishman NO, Goodman EL, Kravitz GR, Leggett JE, Moehring RW, Newland JG, Robinson PA, Spivak ES, Tamma PD, Chambers HF
• PBP4: A New Perspective on Staphylococcus aureus β-Lactam Resistance.
  Microorganisms 2018 da Costa TM, de Oliveira CR, Chambers HF, Chatterjee SS
• PBP4 activity and its overexpression are necessary for PBP4-mediated high-level β-lactam resistance.
  The Journal of antimicrobial chemotherapy 2018 Basuino L, Jousselin A, Alexander JAN, Strynadka NCJ, Pinho MG, Chambers HF, Chatterjee SS
• Cellulitis and Soft Tissue Infections.
  Annals of internal medicine 2018 Bystritsky R, Chambers H
• A Trial of Antibiotics for Smaller Skin Abscesses.
  The New England journal of medicine 2017 Daum RS, Kumar N, Chambers HF
• Sulfamethoxazole-Trimethoprim (Cotrimoxazole) for Skin and Soft Tissue Infections Including Impetigo, Cellulitis, and Abscess.
  Open forum infectious diseases 2017 Bowen AC, Carapetis JR, Currie BJ, Fowler V, Chambers HF, Tong SYC
• PBP4 Mediates β-Lactam Resistance by Altered Function.
  Antimicrobial agents and chemotherapy 2017 Chatterjee SS, Chen L, Gilbert A, da Costa TM, Nair V, Datta SK, Kreiswirth BN, Chambers HF
• Prevalence of Slow-Growth Vancomycin Nonsusceptibility in Methicillin-Resistant Staphylococcus aureus.
  Antimicrobial agents and chemotherapy 2017 Katayama Y, Azechi T, Miyazaki M, Takata T, Sekine M, Matsui H, Hanaki H, Yahara K, Sasano H, Asakura K, Takaku T, Ochiai T, Komatsu N, Chambers HF
• Disabling Dactylitis and Tenosynovitis Due to Mycobacterium haemophilum in a Patient With Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome.
  Open forum infectious diseases 2017 Woodworth MH, Marquez C, Chambers H, Luetkemeyer A
• Antimicrobial Stewardship Approaches in the Intensive Care Unit.
  Infectious disease clinics of North America 2017 Doernberg SB, Chambers HF
• A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses.
  The New England journal of medicine 2017 Daum RS, Miller LG, Immergluck L, Fritz S, Creech CB, Young D, Kumar N, Downing M, Pettibone S, Hoagland R, Eells SJ, Boyle MG, Parker TC, Chambers HF, DMID 07-0051 Team
• Correction for Evans et al., "Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics To Identify Susceptibility and Resistance to Carbapenems against Acinetobacter spp. in PRIMERS III".
  Journal of clinical microbiology 2017 Evans SR, Hujer AM, Jiang H, Hill CB, Hujer KM, Mediavilla JR, Manca C, Tran TTT, Domitrovic TN, Higgins PG, Seifert H, Kreiswirth BN, Patel R, Jacobs MR, Chen L, Sampath R, Hall T, Marzan C, Fowler …
• High-Level Resistance of Staphylococcus aureus to β-Lactam Antibiotics Mediated by Penicillin-Binding Protein 4 (PBP4).
  Antimicrobial agents and chemotherapy 2017 Hamilton SM, Alexander JAN, Choo EJ, Basuino L, da Costa TM, Severin A, Chung M, Aedo S, Strynadka NCJ, Tomasz A, Chatterjee SS, Chambers HF
• Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
  Antimicrobial agents and chemotherapy 2017 Marshall S, Hujer AM, Rojas LJ, Papp-Wallace KM, Humphries RM, Spellberg B, Hujer KM, Marshall EK, Rudin SD, Perez F, Wilson BM, Wasserman RB, Chikowski L, Paterson DL, Vila AJ, van Duin D, Kreiswirth…
• The Antibacterial Resistance Leadership Group: Progress Report and Work in Progress.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2017 Chambers HF, Cross HR, Evans SR, Kreiswirth BN, Fowler VG, Antibacterial Resistance Leadership Group (ARLG)
• Transforming Concepts Into Clinical Trials and Creating a Multisite Network: The Leadership and Operations Center of the Antibacterial Resistance Leadership Group.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2017 Cross HR, Harris A, Arias RM, Chambers HF, Fowler VG
• Ceftaroline-Resistant, Daptomycin-Tolerant, and Heterogeneous Vancomycin-Intermediate Methicillin-Resistant Staphylococcus aureus Causing Infective Endocarditis.
  Antimicrobial agents and chemotherapy 2017 Nigo M, Diaz L, Carvajal LP, Tran TT, Rios R, Panesso D, Garavito JD, Miller WR, Wanger A, Weinstock G, Munita JM, Arias CA, Chambers HF
• Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics To Identify Susceptibility and Resistance to Carbapenems against Acinetobacter spp. in PRIMERS III.
  Journal of clinical microbiology 2016 Evans SR, Hujer AM, Jiang H, Hill CB, Hujer KM, Mediavilla JR, Manca C, Tran TT, Domitrovic TN, Higgins PG, Seifert H, Kreiswirth BN, Patel R, Jacobs MR, Chen L, Sampath R, Hall T, Marzan C, Fowler VG…
• Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.
  Infection & chemotherapy 2016 Choo EJ, Chambers HF
• IVIG-mediated protection against necrotizing pneumonia caused by MRSA.
  Science translational medicine 2016 Diep BA, Le VT, Badiou C, Le HN, Pinheiro MG, Duong AH, Wang X, Dip EC, Aguiar-Alves F, Basuino L, Marbach H, Mai TT, Sarda MN, Kajikawa O, Matute-Bello G, Tkaczyk C, Rasigade JP, Sellman BR, Chambers…
• Vancomycin MIC Does Not Predict 90-Day Mortality, Readmission, or Recurrence in a Prospective Cohort of Adults with Staphylococcus aureus Bacteremia.
  Antimicrobial agents and chemotherapy 2016 Baxi SM, Clemenzi-Allen A, Gahbauer A, Deck D, Imp B, Vittinghoff E, Chambers HF, Doernberg S
• Cefazolin versus Nafcillin for Methicillin-Sensitive Staphylococcus aureus Bloodstream Infection in a California Tertiary Medical Center.
  Antimicrobial agents and chemotherapy 2016 Pollett S, Baxi SM, Rutherford GW, Doernberg SB, Bacchetti P, Chambers HF
• Daptomycin-β-Lactam Combinations in a Rabbit Model of Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Endocarditis.
  Antimicrobial agents and chemotherapy 2016 Chambers HF, Basuino L, Hamilton SM, Choo EJ, Moise P
• PBP 4 Mediates High-Level Resistance to New-Generation Cephalosporins in Staphylococcus aureus.
  Antimicrobial agents and chemotherapy 2016 Chan LC, Gilbert A, Basuino L, da Costa TM, Hamilton SM, Dos Santos KR, Chambers HF, Chatterjee SS
• Reply to Lesho and Clifford.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016 Evans S, Kreiswirth B, Fowler V, Chambers H, Patel R, Hujer AM, Perez F, Bonomo RA
• New Societal Approaches to Empowering Antibiotic Stewardship.
  JAMA 2016 Spellberg B, Srinivasan A, Chambers HF
• Whole-Genome Sequencing of Methicillin-Resistant Staphylococcus aureus Resistant to Fifth-Generation Cephalosporins Reveals Potential Non-mecA Mechanisms of Resistance.
  PloS one 2016 Greninger AL, Chatterjee SS, Chan LC, Hamilton SM, Chambers HF, Chiu CY
• Reply to Phillips, Morris, and Walker.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2015 Evans S, Follmann D, Schoenfeld D, Fowler VG, Chambers HF
• Rapid Molecular Diagnostics, Antibiotic Treatment Decisions, and Developing Approaches to Inform Empiric Therapy: PRIMERS I and II.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2015 Evans SR, Hujer AM, Jiang H, Hujer KM, Hall T, Marzan C, Jacobs MR, Sampath R, Ecker DJ, Manca C, Chavda K, Zhang P, Fernandez H, Chen L, Mediavilla JR, Hill CB, Perez F, Caliendo AM, Fowler VG, …
• Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR).
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2015 Evans SR, Rubin D, Follmann D, Pennello G, Huskins WC, Powers JH, Schoenfeld D, Chuang-Stein C, Cosgrove SE, Fowler VG, Lautenbach E, Chambers HF
• Antibacterial Treatment for Uncomplicated Skin Infections.
  The New England journal of medicine 2015 Miller LG, Daum RS, Chambers HF
• USA300 and USA500 clonal lineages of Staphylococcus aureus do not produce a capsular polysaccharide due to conserved mutations in the cap5 locus.
  mBio 2015 Boyle-Vavra S, Li X, Alam MT, Read TD, Sieth J, Cywes-Bentley C, Dobbins G, David MZ, Kumar N, Eells SJ, Miller LG, Boxrud DJ, Chambers HF, Lynfield R, Lee JC, Daum RS
• Comparative efficacies of tedizolid phosphate, vancomycin, and daptomycin in a rabbit model of methicillin-resistant Staphylococcus aureus endocarditis.
  Antimicrobial agents and chemotherapy 2015 Chan LC, Basuino L, Dip EC, Chambers HF
• Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections.
  The New England journal of medicine 2015 Miller LG, Daum RS, Creech CB, Young D, Downing MD, Eells SJ, Pettibone S, Hoagland RJ, Chambers HF, DMID 07-0051 Team
• Ceftobiprole- and ceftaroline-resistant methicillin-resistant Staphylococcus aureus.
  Antimicrobial agents and chemotherapy 2015 Chan LC, Basuino L, Diep B, Hamilton S, Chatterjee SS, Chambers HF
• Probability of eradication using vancomycin alone or in combination for methicillin-resistant Staphylococcus aureus bacteremia.
  Antimicrobial agents and chemotherapy 2014 Chambers HF
• Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2014 Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan SL, Montoya JG, Wade JC, Infectious Diseases Society of America
• Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2014 Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan SL, Montoya JG, Wade JC
• Pharmacology and the treatment of complicated skin and skin-structure infections.
  The New England journal of medicine 2014 Chambers HF
• Staphylococcus aureus bacteremia at 5 US academic medical centers, 2008-2011: significant geographic variation in community-onset infections.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2014 David MZ, Daum RS, Bayer AS, Chambers HF, Fowler VG, Miller LG, Ostrowsky B, Baesa A, Boyle-Vavra S, Eells SJ, Garcia-Houchins S, Gialanella P, Macias-Gil R, Rude TH, Ruffin F, Sieth JJ, Volinski J, …
• Global gene expression of methicillin-resistant Staphylococcus aureus USA300 during human and mouse infection.
  The Journal of infectious diseases 2013 Date SV, Modrusan Z, Lawrence M, Morisaki JH, Toy K, Shah IM, Kim J, Park S, Xu M, Basuino L, Chan L, Zeitschel D, Chambers HF, Tan MW, Brown EJ, Diep BA, Hazenbos WL
• Effects of linezolid on suppressing in vivo production of staphylococcal toxins and improving survival outcomes in a rabbit model of methicillin-resistant Staphylococcus aureus necrotizing pneumonia.
  The Journal of infectious diseases 2013 Diep BA, Afasizheva A, Le HN, Kajikawa O, Matute-Bello G, Tkaczyk C, Sellman B, Badiou C, Lina G, Chambers HF
• Epidemiologic Similarities in Pediatric Community-Associated Methicillin-Resistant and Methicillin-Sensitive Staphylococcus aureus in the San Francisco Bay Area.
  Journal of the Pediatric Infectious Diseases Society 2012 Hsiang MS, Shiau R, Nadle J, Chan L, Lee B, Chambers HF, Pan E
• Concurrent epidemics of skin and soft tissue infection and bloodstream infection due to community-associated methicillin-resistant Staphylococcus aureus.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2012 Tattevin P, Schwartz BS, Graber CJ, Volinski J, Bhukhen A, Bhukhen A, Mai TT, Vo NH, Dang DN, Phan TH, Basuino L, Perdreau-Remington F, Chambers HF, Diep BA
• Does doxycycline protect against development of Clostridium difficile infection?
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2012 Doernberg SB, Winston LG, Deck DH, Chambers HF
• Genetic pathway in acquisition and loss of vancomycin resistance in a methicillin resistant Staphylococcus aureus (MRSA) strain of clonal type USA300.
  PLoS pathogens 2012 Gardete S, Kim C, Hartmann BM, Mwangi M, Roux CM, Dunman PM, Chambers HF, Tomasz A
• Clonality of Staphylococcus aureus colonization over time in attendees of a camp for children with chronic dermatoses.
  Pediatric dermatology 2011 Graber CJ, Shane AL, Weintrub P, Chambers HF
• Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2011 Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF
• Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2011 Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF, Infectious Diseases Society of America
• A mecA-negative strain of methicillin-resistant Staphylococcus aureus with high-level β-lactam resistance contains mutations in three genes.
  Antimicrobial agents and chemotherapy 2010 Banerjee R, Gretes M, Harlem C, Basuino L, Chambers HF
• Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-Valentine leukocidin-induced lung inflammation and injury.
  Proceedings of the National Academy of Sciences of the United States of America 2010 Diep BA, Chan L, Tattevin P, Kajikawa O, Martin TR, Basuino L, Mai TT, Marbach H, Braughton KR, Whitney AR, Gardner DJ, Fan X, Tseng CW, Liu GY, Badiou C, Etienne J, Lina G, Matthay MA, DeLeo FR, …
• Community-associated meticillin-resistant Staphylococcus aureus.
  Lancet (London, England) 2010 DeLeo FR, Otto M, Kreiswirth BN, Chambers HF
• Characterization of baseline methicillin-resistant Staphylococcus aureus isolates recovered from phase IV clinical trial for linezolid.
  Journal of clinical microbiology 2009 Mendes RE, Sader HS, Deshpande LM, Diep BA, Chambers HF, Jones RN
• Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus.
  Antimicrobial agents and chemotherapy 2009 Tattevin P, Basuino L, Bauer D, Diep BA, Chambers HF
• Reemergence of antibiotic-resistant Staphylococcus aureus in the genomics era.
  The Journal of clinical investigation 2009 DeLeo FR, Chambers HF
• Waves of resistance: Staphylococcus aureus in the antibiotic era.
  Nature reviews. Microbiology 2009 Chambers HF, Deleo FR
• Coming home with MRSA.
  Archives of internal medicine 2009 Winston L, Chambers H
• Doxycycline, not minocycline, induces its own resistance in multidrug-resistant, community-associated methicillin-resistant Staphylococcus aureus clone USA300.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009 Schwartz BS, Graber CJ, Diep BA, Basuino L, Perdreau-Remington F, Chambers HF
• Subinhibitory fluoroquinolone exposure selects for reduced beta-lactam susceptibility in methicillin-resistant Staphylococcus aureus and alterations in the SOS-mediated response.
  Research in microbiology 2009 Tattevin P, Basuino L, Chambers HF
• Evolution of virulence in epidemic community-associated methicillin-resistant Staphylococcus aureus.
  Proceedings of the National Academy of Sciences of the United States of America 2009 Li M, Diep BA, Villaruz AE, Braughton KR, Jiang X, DeLeo FR, Chambers HF, Lu Y, Otto M
• Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009 Cosgrove SE, Vigliani GA, Fowler VG, Abrutyn E, Corey GR, Levine DP, Rupp ME, Chambers HF, Karchmer AW, Boucher HW
• Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.
  Antimicrobial agents and chemotherapy 2009 Chambers HF, Basuino L, Diep BA, Steenbergen J, Zhang S, Tattevin P, Alder J
• Recurrence of skin and soft tissue infection caused by methicillin-resistant Staphylococcus aureus in a HIV primary care clinic.
  Journal of acquired immune deficiency syndromes (1999) 2008 Graber CJ, Jacobson MA, Perdreau-Remington F, Chambers HF, Diep BA
• Contribution of Panton-Valentine leukocidin in community-associated methicillin-resistant Staphylococcus aureus pathogenesis.
  PloS one 2008 Diep BA, Palazzolo-Ballance AM, Tattevin P, Basuino L, Braughton KR, Whitney AR, Chen L, Kreiswirth BN, Otto M, DeLeo FR, Chambers HF
• Clinical decisions. Management of skin and soft-tissue infection.
  The New England journal of medicine 2008 Chambers HF, Moellering RC, Kamitsuka P
• National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections.
  Archives of internal medicine 2008 Hersh AL, Chambers HF, Maselli JH, Gonzales R
• A population-based study of the incidence and molecular epidemiology of methicillin-resistant Staphylococcus aureus disease in San Francisco, 2004-2005.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008 Liu C, Graber CJ, Karr M, Diep BA, Basuino L, Schwartz BS, Enright MC, O'Hanlon SJ, Thomas JC, Perdreau-Remington F, Gordon S, Gunthorpe H, Jacobs R, Jensen P, Leoung G, Rumack JS, Chambers HF
• Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008 Stryjewski ME, Chambers HF
• The arginine catabolic mobile element and staphylococcal chromosomal cassette mec linkage: convergence of virulence and resistance in the USA300 clone of methicillin-resistant Staphylococcus aureus.
  The Journal of infectious diseases 2008 Diep BA, Stone GG, Basuino L, Graber CJ, Miller A, des Etages SA, Jones A, Palazzolo-Ballance AM, Perdreau-Remington F, Sensabaugh GF, DeLeo FR, Chambers HF
• In vitro selection and characterization of ceftobiprole-resistant methicillin-resistant Staphylococcus aureus.
  Antimicrobial agents and chemotherapy 2008 Banerjee R, Gretes M, Basuino L, Strynadka N, Chambers HF
• Determining whether methicillin-resistant Staphylococcus aureus is associated with health care.
  JAMA 2008 David MZ, Siegel JD, Chambers HF, Daum RS
• Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men.
  Annals of internal medicine 2008 Diep BA, Chambers HF, Graber CJ, Szumowski JD, Miller LG, Han LL, Chen JH, Lin F, Lin J, Phan TH, Carleton HA, McDougal LK, Tenover FC, Cohen DE, Mayer KH, Sensabaugh GF, Perdreau-Remington F
• Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection.
  Antimicrobial agents and chemotherapy 2007 Rajendran PM, Young D, Maurer T, Chambers H, Perdreau-Remington F, Ro P, Harris H
• Combating the growing problem of methicillin-resistant Staphylococcus aureus: do the newer antibiotics represent a better alternative to vancomycin?
  Expert review of anti-infective therapy 2007 Chambers HF, Hegde SS
• Mechanism of cell surface expression of the Streptococcus mitis platelet binding proteins PblA and PblB.
  Molecular microbiology 2007 Mitchell J, Siboo IR, Takamatsu D, Chambers HF, Sullam PM
• Intermediate vancomycin susceptibility in a community-associated MRSA clone.
  Emerging infectious diseases 2007 Graber CJ, Wong MK, Carleton HA, Perdreau-Remington F, Haller BL, Chambers HF
• Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.
  The New England journal of medicine 2006 Fowler VG, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, …
• Ophthalmic manifestations of infections caused by the USA300 clone of community-associated methicillin-resistant Staphylococcus aureus.
  Ophthalmology 2006 Rutar T, Chambers HF, Crawford JB, Perdreau-Remington F, Zwick OM, Karr M, Diehn JJ, Cockerham KP
• Diabetic ketoacidosis precipitated by Staphylococcus aureus abscess and bacteremia due to acupuncture: case report and review of the literature.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006 Seeley EJ, Chambers HF
• Ceftobiprole: in-vivo profile of a bactericidal cephalosporin.
  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2006 Chambers HF
• Practice guidelines for the diagnosis and management of skin and soft-tissue infections.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005 Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan EL, Montoya JG, Wade JC, Infectious Diseases Society of America
• Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
  Antimicrobial agents and chemotherapy 2005 Madrigal AG, Basuino L, Chambers HF
• Imipenem for treatment of tuberculosis in mice and humans.
  Antimicrobial agents and chemotherapy 2005 Chambers HF, Turner J, Schecter GF, Kawamura M, Hopewell PC
• Genetic background affects stability of mecA in Staphylococcus aureus.
  Journal of clinical microbiology 2005 Katayama Y, Robinson DA, Enright MC, Chambers HF
• Low colonization prevalence of Staphylococcus aureus with reduced vancomycin susceptibility among patients undergoing hemodialysis in the San Francisco Bay area.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005 Eguia JM, Liu C, Moore M, Wrone EM, Pont J, Gerberding JL, Chambers HF
• Community-associated MRSA--resistance and virulence converge.
  The New England journal of medicine 2005 Chambers HF
• Role of SraP, a Serine-Rich Surface Protein of Staphylococcus aureus, in binding to human platelets.
  Infection and immunity 2005 Siboo IR, Chambers HF, Sullam PM
• Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus.
  Antimicrobial agents and chemotherapy 2005 Chambers HF
• Impact of a formulary switch from ticarcillin-clavulanate to piperacillin-tazobactam on colonization with vancomycin-resistant enterococci.
  American journal of infection control 2004 Winston LG, Charlebois ED, Pang S, Bangsberg DR, Perdreau-Remington F, Chambers HF
• An epidemic of methicillin-resistant Staphylococcus aureus soft tissue infections among medically underserved patients.
  Archives of surgery (Chicago, Ill. : 1960) 2004 Young DM, Harris HW, Charlebois ED, Chambers H, Campbell A, Perdreau-Remington F, Lee C, Mankani M, Mackersie R, Schecter WP
• Crystal structures of the Apo and penicillin-acylated forms of the BlaR1 beta-lactam sensor of Staphylococcus aureus.
  The Journal of biological chemistry 2004 Wilke MS, Hills TL, Zhang HZ, Chambers HF, Strynadka NC
• Origins of community strains of methicillin-resistant Staphylococcus aureus.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004 Charlebois ED, Perdreau-Remington F, Kreiswirth B, Bangsberg DR, Ciccarone D, Diep BA, Ng VL, Chansky K, Edlin BR, Edlin B, Chambers HF
• API 20 strep identification system may incorrectly speciate enterococci with low level resistance to vancomycin.
  Diagnostic microbiology and infectious disease 2004 Winston LG, Pang S, Haller BL, Wong M, Chambers HF, Perdreau-Remington F
• Mupirocin prophylaxis misses by a nose.
  Annals of internal medicine 2004 Chambers HF, Winston LG
• Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004 Carpenter CF, Chambers HF
• PBP 2a mutations producing very-high-level resistance to beta-lactams.
  Antimicrobial agents and chemotherapy 2004 Katayama Y, Zhang HZ, Chambers HF
• Community-acquired Methicillin-resistant Staphylococcus aureus: Epidemiology and Potential Virulence Factors.
  Current infectious disease reports 2003 Eguia JM, Chambers HF
• Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods.
  Antimicrobial agents and chemotherapy 2003 Liu C, Chambers HF
• Jumping the barrier to beta-lactam resistance in Staphylococcus aureus.
  Journal of bacteriology 2003 Katayama Y, Zhang HZ, Hong D, Chambers HF
• Solving staphylococcal resistance to beta-lactams.
  Trends in microbiology 2003 Chambers HF
• Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis.
  Antimicrobial agents and chemotherapy 2003 Moore MR, Perdreau-Remington F, Chambers HF
• Methicillin-resistant staphylococci and their treatment in the intensive care unit.
  Seminars in respiratory and critical care medicine 2003 Eguia JM, Chambers HF
• Effect of disruption of Staphylococcus aureus PBP4 gene on resistance to beta-lactam antibiotics.
  Microbial drug resistance (Larchmont, N.Y.) 2003 Katayama Y, Zhang HZ, Chambers HF
• Epidemiology of vancomycin-resistant Enterococcus faecium under a selective isolation policy at an urban county hospital.
  American journal of infection control 2002 Winston LG, Bangsberg DR, Chambers HF, Felt SC, Rosen JI, Charlebois ED, Wong M, Steele L, Gerberding JL, Perdreau-Remington F
• Population-based community prevalence of methicillin-resistant Staphylococcus aureus in the urban poor of San Francisco.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2002 Charlebois ED, Bangsberg DR, Moss NJ, Moore MR, Moss AR, Chambers HF, Perdreau-Remington F
• Identifying pulmonary tuberculosis in patients with negative sputum smear results.
  Chest 2001 Kanaya AM, Glidden DV, Chambers HF
• The changing epidemiology of Staphylococcus aureus?
  Emerging infectious diseases 2001 Chambers HF
• Methicillin-resistant Staphylococcus aureus. Mechanisms of resistance and implications for treatment.
  Postgraduate medicine 2001 Chambers HF
• Efficacy of levofloxacin for experimental aortic-valve endocarditis in rabbits infected with viridans group streptococcus or Staphylococcus aureus.
  Antimicrobial agents and chemotherapy 1999 Chambers HF, Xiang Q, Chow LL, Hackbarth C
• A randomized clinical trial of mupirocin in the eradication of Staphylococcus aureus nasal carriage in human immunodeficiency virus disease.
  The Journal of infectious diseases 1999 Martin JN, Perdreau-Remington F, Kartalija M, Pasi OG, Webb M, Gerberding JL, Chambers HF, Täuber MG, Lee BL
• Comparative efficacy of trovafloxacin in experimental endocarditis caused by ciprofloxacin-sensitive, methicillin-resistant Staphylococcus aureus.
  Antimicrobial agents and chemotherapy 1998 Kim YS, Liu Q, Chow LL, Chambers HF, Täuber MG
• Suppurative parotitis.
  The Western journal of medicine 1998 Sheppard DC, Chambers HF
• Activity of amoxicillin/clavulanate in patients with tuberculosis.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1998 Chambers HF, Kocagöz T, Sipit T, Turner J, Hopewell PC
• Cloning and sequence analysis of a class A beta-lactamase from Mycobacterium tuberculosis H37Ra.
  Antimicrobial agents and chemotherapy 1997 Hackbarth CJ, Unsal I, Chambers HF
• Burden of Mycobacterium tuberculosis in sputum samples can be reliably determined using a quantitative, non-radioactive polymerase chain reaction assay.
  Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 1996 Sweet-Cordero EA, Chambers HF, Cicero-Sabido R, Santos-Preciado JI
• Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra.
  Antimicrobial agents and chemotherapy 1996 Kocagöz T, Hackbarth CJ, Unsal I, Rosenberg EY, Nikaido H, Chambers HF
• Treatment of Staphylococcus aureus catheter-related infection and infective endocarditis with granulocyte colony-stimulating factor in the experimental rabbit model.
  Antimicrobial agents and chemotherapy 1996 Frank U, Chambers HF
• Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine.
  Clinical pharmacology and therapeutics 1996 Lee BL, Täuber MG, Sadler B, Goldstein D, Chambers HF
• Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis?
  Antimicrobial agents and chemotherapy 1995 Chambers HF, Moreau D, Yajko D, Miick C, Wagner C, Hackbarth C, Kocagöz S, Rosenberg E, Hadley WK, Nikaido H
• Quantitative culture of Mycobacterium tuberculosis from clinical sputum specimens and dilution endpoint of its detection by the Amplicor PCR assay.
  Journal of clinical microbiology 1995 Yajko DM, Wagner C, Tevere VJ, Kocagöz T, Hadley WK, Chambers HF
• Ampicillin, sulbactam, and rifampin combination treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis in rabbits.
  The Journal of infectious diseases 1995 Chambers HF, Kartalija M, Sande M
• In vitro and in vivo antistaphylococcal activities of L-695,256, a carbapenem with high affinity for the penicillin-binding protein PBP 2a.
  Antimicrobial agents and chemotherapy 1995 Chambers HF
• Point mutations in Staphylococcus aureus PBP 2 gene affect penicillin-binding kinetics and are associated with resistance.
  Antimicrobial agents and chemotherapy 1995 Hackbarth CJ, Kocagoz T, Kocagoz S, Chambers HF
• Altered production of penicillin-binding protein 2a can affect phenotypic expression of methicillin resistance in Staphylococcus aureus.
  Antimicrobial agents and chemotherapy 1994 Hackbarth CJ, Miick C, Chambers HF
• Efficacy of cefoperazone in combination with sulbactam in experimental Staphylococcus aureus endocarditis in rabbits.
  The Journal of antimicrobial chemotherapy 1993 Chambers HF, Fournier MA
• Detection of methicillin-resistant staphylococci.
  Infectious disease clinics of North America 1993 Chambers HF
• blaI and blaR1 regulate beta-lactamase and PBP 2a production in methicillin-resistant Staphylococcus aureus.
  Antimicrobial agents and chemotherapy 1993 Hackbarth CJ, Chambers HF
• Short-course combination and oral therapies of Staphylococcus aureus endocarditis.
  Infectious disease clinics of North America 1993 Chambers HF
• Studies of RP 59500 in vitro and in a rabbit model of aortic valve endocarditis caused by methicillin-resistant Staphylococcus aureus.
  The Journal of antimicrobial chemotherapy 1992 Chambers HF
• Characterization of penicillin-binding protein 2 of Staphylococcus aureus: deacylation reaction and identification of two penicillin-binding peptides.
  Antimicrobial agents and chemotherapy 1992 Chambers HF, Miick C
• Comparison of conventional susceptibility tests with direct detection of penicillin-binding protein 2a in borderline oxacillin-resistant strains of Staphylococcus aureus.
  Antimicrobial agents and chemotherapy 1991 Gerberding JL, Miick C, Liu HH, Chambers HF
• Effect of protein binding of daptomycin on MIC and antibacterial activity.
  Antimicrobial agents and chemotherapy 1991 Lee BL, Sachdeva M, Chambers HF
• Borderline susceptibility to antistaphylococcal penicillins is not conferred exclusively by the hyperproduction of beta-lactamase.
  Antimicrobial agents and chemotherapy 1991 Barg N, Chambers H, Kernodle D
• Treatment of infection and colonization caused by methicillin-resistant Staphylococcus aureus.
  Infection control and hospital epidemiology 1991 Chambers HF
• Binding affinity for penicillin-binding protein 2a correlates with in vivo activity of beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus.
  The Journal of infectious diseases 1990 Chambers HF, Sachdeva M, Kennedy S
• Characterization of mechanisms of resistance to beta-lactam antibiotics in methicillin-resistant strains of Staphylococcus saprophyticus.
  Antimicrobial agents and chemotherapy 1990 Stratton CW, Gelfand MS, Gerberding JL, Chambers HF
• Binding of beta-lactam antibiotics to penicillin-binding proteins in methicillin-resistant Staphylococcus aureus.
  The Journal of infectious diseases 1990 Chambers HF, Sachdeva M
• Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users.
  Antimicrobial agents and chemotherapy 1990 Small PM, Chambers HF
• Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis.
  Antimicrobial agents and chemotherapy 1990 Chambers HF, Kennedy S
• Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin.
  Lancet (London, England) 1989 Dworkin RJ, Lee BL, Sande MA, Chambers HF
• Evaluation of cilofungin (LY121019) for treatment of experimental Candida albicans endocarditis in rabbits.
  Antimicrobial agents and chemotherapy 1989 Padula A, Chambers HF
• Daptomycin (LY146032) for prevention and treatment of experimental aortic valve endocarditis in rabbits.
  Antimicrobial agents and chemotherapy 1989 Kennedy S, Chambers HF
• Methicillin-resistant staphylococci: detection methods and treatment of infections.
  Antimicrobial agents and chemotherapy 1989 Hackbarth CJ, Chambers HF
• Methicillin-resistant staphylococci: genetics and mechanisms of resistance.
  Antimicrobial agents and chemotherapy 1989 Hackbarth CJ, Chambers HF
• Low-level methicillin resistance in strains of Staphylococcus aureus.
  Antimicrobial agents and chemotherapy 1989 Chambers HF, Archer G, Matsuhashi M
• Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy.
  Annals of internal medicine 1988 Chambers HF, Miller RT, Newman MD
• Staphylococcus aureus bacteremia and recurrent staphylococcal infection in patients with acquired immunodeficiency syndrome and AIDS-related complex.
  The American journal of medicine 1988 Jacobson MA, Gellermann H, Chambers H
• Methicillin-resistant staphylococci.
  Clinical microbiology reviews 1988 Chambers HF
• Coagulase-negative staphylococci resistant to beta-lactam antibiotics in vivo produce penicillin-binding protein 2a.
  Antimicrobial agents and chemotherapy 1987 Chambers HF
• Effect of NaCl and nafcillin on penicillin-binding protein 2a and heterogeneous expression of methicillin resistance in Staphylococcus aureus.
  Antimicrobial agents and chemotherapy 1987 Chambers HF, Hackbarth CJ
• Comparative activity of CGP 31608, nafcillin, cefamandole, imipenem, and vancomycin against methicillin-susceptible and methicillin-resistant staphylococci.
  Antimicrobial agents and chemotherapy 1987 Sachdeva M, Hackbarth C, Stella FB, Chambers HF
• Emergence of resistance to cephalothin and gentamicin during combination therapy for methicillin-resistant Staphylococcus aureus endocarditis in rabbits.
  The Journal of infectious diseases 1987 Chambers HF, Miller MH
• Efficacy of ciprofloxacin for experimental endocarditis caused by methicillin-susceptible or -resistant strains of Staphylococcus aureus.
  Antimicrobial agents and chemotherapy 1986 Carpenter TC, Hackbarth CJ, Chambers HF, Sande MA
• Serum bactericidal activity of rifampin in combination with other antimicrobial agents against Staphylococcus aureus.
  Antimicrobial agents and chemotherapy 1986 Hackbarth CJ, Chambers HF, Sande MA
• Increased amounts of a novel penicillin-binding protein in a strain of methicillin-resistant Staphylococcus aureus exposed to nafcillin.
  The Journal of clinical investigation 1985 Chambers HF, Hartman BJ, Tomasz A
• Pefloxacin therapy for experimental endocarditis caused by methicillin-susceptible or methicillin-resistant strains of Staphylococcus aureus.
  Antimicrobial agents and chemotherapy 1985 Sullam PM, Täuber MG, Hackbarth CJ, Chambers HF, Scott KG, Sande MA
• Failure of a once-daily regimen of cefonicid for treatment of endocarditis due to Staphylococcus aureus.
  Reviews of infectious diseases 1984 Chambers HF, Mills J, Drake TA, Sande MA
• Teicoplanin versus nafcillin and vancomycin in the treatment of experimental endocarditis caused by methicillin-susceptible or -resistant Staphylococcus aureus.
  Antimicrobial agents and chemotherapy 1984 Chambers HF, Sande MA
• Endocarditis due to methicillin-resistant Staphylococcus aureus in rabbits: expression of resistance to beta-lactam antibiotics in vivo and in vitro.
  The Journal of infectious diseases 1984 Chambers HF, Hackbarth CJ, Drake TA, Rusnak MG, Sande MA
• Staphylococcus aureus endocarditis: clinical manifestations in addicts and nonaddicts.
  Medicine 1983 Chambers HF, Korzeniowski OM, Sande MA